Renal anemia is a major complication in chronic kidney disease (CKD). Iron supplementation, as well as erythropoiesisstimulating agents, are widely used for treatment of renal anemia. However, excess iron causes oxidative stress via the Fenton reaction, and iron supplementation might damage remnant renal function including erythropoietin (EPO) production in CKD. EPO gene expression was suppressed in mice following direct iron treatment. Hypoxia-inducible factor-2 alpha (HIF-2α), a positive regulator of the EPO gene, was also diminished in the kidney of mice following iron treatment. Anemia-induced increase in renal EPO and HIF-2α expression was inhibited by iron treatment. In in vitro experiments using EPO-producing HepG2 cells, iron stimulation reduced the expression of the EPO gene, as well as HIF-2α. Moreover, iron treatment augmented oxidative stress, and iron-induced reduction of EPO and HIF-2α expression was restored by tempol, an antioxidant compound. HIF-2α interaction with the Epo promoter was inhibited by iron treatment, and was restored by tempol. These findings suggested that iron supplementation reduced EPO gene expression via an oxidative stress-HIF-2α-dependent signaling pathway.
The incidence of chronic kidney disease (CKD) has increased worldwide, and CKD worsens morbidity and mortality in the general population. 1, 2 The progression of CKD results in endstage renal failure, which requires treatment by hemodialysis or renal transplantation. In addition, a variety of complications arises during the course of CKD. Cardiovascular disease, a major complication of CKD, also leads to worse outcomes in CKD patients. 3 Renal anemia is commonly seen in individuals with CKD due to insufficient erythropoietin (EPO) production within the diseased kidney. 4, 5 Therefore, patients with end-stage renal disease receive erythropoiesisstimulating agent (ESA) for the treatment of renal anemia.
Iron supplementation, in addition to ESA, is often used for the treatment of renal anemia. 6 However, patients with CKD often show functional iron deficiency, rather than absolute iron deficiency, characterized by impaired iron release from body iron stores. 7 Disturbance of iron utilization in CKD occurs due to ferroportin (a cellular iron exporter) degradation resulting from increased hepcidin production. 8, 9 Hepcidin is positively controlled by iron stores. 10 Therefore, iron treatment further exacerbates impaired iron utilization via hepcidin elevation and results in over accumulation of disused iron in organs of CKD individuals. Actually, adverse effects of iron supplementation on organs have been directly observed in several studies. Iron sucrose treatment exacerbates endothelial dysfunction in healthy subjects 11 and atherosclerotic change through enhancement of oxidative stress in a CKD mouse model. 12 Intravenous iron also causes oxidative stress and transient proteinuria, tubular damage, and inflammatory cytokine production in patients with CKD. 13, 14 Thus, parenteral iron supplementation might aggravate and cause complications in CKD through oxidative stress production. Furthermore, iron might exacerbate erythropoietin production consequent to remnant kidney injury, however, the effect of iron on EPO regulation has not been elucidated.
Here, we demonstrate that saccharated ferric oxide (SFO) reduced renal EPO expression through iron-induced oxidative stress production-dependent inactivation of hypoxia-inducible factor-2α (HIF-2α). Our findings suggest that therapeutic iron supplementation has a harmful effect on EPO regulation in remnant kidney function, causing a vicious cycle of CKD progression.
MATERIALS AND METHODS Materials
We purchased saccharated ferric oxide (SFO), cobalt chloride (CoCl 2 ), tempol, and dimethyloxallyl glycine (DMOG) from Nichi-Iko Pharmaceutical, Co., Ltd. (Toyama, Japan), Wako Pure Chemical Industries (Osaka, Japan), Sigma-Aldrich (St Louis, MO, USA), and Cayman Chemical Company (Ann Arbor, MI, USA), respectively. The following commercially available antibodies were used: anti-HIF-2α (R&D Systems, Minneapolis, MN, USA); anti-HIF-1α (Cayman Chemical); anti-PDGF-Rβ (Cell Signaling Technology, Beverly, MA, USA); anti-α-SMA (Sigma-Aldrich, St Louis, MO, USA); anti-Lotus Tetragonolobus Lectin (VECTOR Laboratories, Burlingame, CA, USA); E-cadherin (Cell Signaling Technology); anti-α-tubulin, as a loading control, from Calbiochem (San Diego, CA, USA).
Animal Preparation and Procedure
All experimental procedures were performed in accordance with the guidelines of the Animal Research Committee of Tokushima University Graduate School, and protocols were approved by the Institutional Review Board for animal protection. Eight-week-old C57BL/6J mice were obtained from Nippon CLEA (Tokyo, Japan) and they were maintained with free access to water and food (Type NMF; Oriental Yeast, Tokyo, Japan). The unilateral ureteral obstruction (UUO) procedure was previously described in detail. 15 Our mouse model of chronic iron treatment was produced as previously described. 12 Briefly, intraperitoneal SFO (2 mg in a volume of 200 μl per 25 g mouse) or the same volume of vehicle was administered for five consecutive days. The mice were killed 24 h after the last iron treatment with an intraperitoneal injection of over-dose pentobarbital, and the kidney was removed and stored at − 80°C until use.
Induction of Anemia by Phlebotomy
Phlebotomy was performed for two consecutive days. Briefly, after anesthesia, approximately 400 μl blood was removed via retroorbital bleeding and was replaced by the same volume of sterile normal saline by a subcutaneous injection. Then, the mice were administered the vehicle or SFO via an intraperitoneal injection and were placed on a heating pad until full recovery. The mice were killed 24 h after the last phlebotomy.
Cell Culture
Although renal EPO-producing cells are suggested to be derived from tubular interstitial cells such as fibroblasts 16, 17 or pericytes, 18 there are no cell lines established. Therefore, HepG2 cells, a human hepatoma cell line, have been used as EPO-producing cells in in vitro experiments. [19] [20] [21] Similarly, we used HepG2 cells to investigate the mechanism of iron on EPO regulation in this study. HepG2 cell was purchased from the Japanese Collection of Research Bioresources (Osaka, Japan). The cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Wako Pure Chemical Industries, Osaka, Japan) according to the protocol. For each experiment, the cells at passage 5-8 were used. The cells were grown to confluence, then transferred to serum-free medium before the start of the experiments. In some experiments, the cells were pretreated with 100 μM CoCl 2 , 200 μM DMOG, and 100 μM tempol for 1 h before stimulation with SFO.
RNA Extraction and Evaluation of mRNA Expression Levels RNA extraction, cDNA synthesis, and quantitative RT-PCR methods have been previously described. 15 Briefly, the tissues or cells were homogenized in RNAiso reagent (Takara Bio, Otsu, Japan). RNA extraction and cDNA synthesis were performed according to the manufacturer's instructions (PrimeScript RT reagent Kit with gDNA Eraser (Perfect Real Time), Takara Bio). Quantitative RT-PCR was performed using the CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA) with THUNDER-BIRD SYBR qPCR Mix (TOYOBO CO., LTD., Osaka, Japan). The expression levels of all target genes were normalized using 36B4 as an internal control. 15 The primer sets used are noted in Table 1 .
Protein Extraction and Western Blot Analysis
Protein preparation and western blotting were performed as previously described. 15 Briefly, the tissues or cell samples were homogenized and sonicated, and then proteins were extracted. The extracted proteins were boiled for 5 min in Laemmli sample buffer and separated using SDS-PAGE. The proteins were transferred to a polyvinylidene fluoride (PVDF) membrane and the membrane was blocked for 1 h at room temperature. Next, the membrane was incubated individually with each primary antibody overnight at 4°C, followed by incubation for 1 h with the secondary antibody. Immunoreactive bands were detected using a chemiluminescence reagent and visualized by exposure onto an X-ray film or by C-DiGit chemiluminescent scanner (LI-COR C-DiGit Blot Scanner, Lincoln, NE, USA). Densitometry of the visualized bands was quantified using Image J 1.38 × software.
Immunohistochemistry in the Kidney
The extracted kidney tissues were embedded in OCT compound (Tissue-Tek, SAKURA Finetek, Tokyo, Japan) and frozen in liquid nitrogen-cold isopentane. Samples were cut into 8-μm sections, dried, and fixed in 4% paraformaldehyde for 10 min. After blocking, the tissue sections were incubated with primary antibodies at 4°C overnight. Antibody distribution was visualized using immunofluorescence (Alexa fluor; Life Technology, Tokyo, Japan). The sections incubated without primary antibody were used as negative controls.
Measurement of Tissue Iron Content
Tissue iron content was measured using an iron assay kit according to the manufacturer's instructions (Metallo assay, Metallogenics, Chiba, Japan) as described previously. 15, 22 Briefly, the extracted kidney tissues were weighed and homogenized in cell lysis buffer. Non-centrifuged crude lysates were additionally sonicated, then added and mixed with 6 N hydrochloric acid to a final concentration of 0.05 M at room temperature for 30 min. After centrifugation, the supernatants were used for iron measurement. Tissue iron concentration was corrected using tissue weight and expressed as μg Fe per gram of wet tissue.
Cell Viability Assay
Cell viability was accessed using CellTiter 96 AQueous nonradioactive cell proliferation assay kit (Promega KK, Tokyo, Japan). 23 Briefly, HepG2 cells were seeded in 96-well plates at 1 × 10 4 cells per well and incubated for 24 h. Subsequently, various concentrations of SFO were added for 24 h and the impact of SFO on cell viability was assessed 1 h after the addition of MTS reagent by measuring absorbance at 490 nm with a plate reader (iMARK microplate reader, Bio-Rad Laboratories).
Detection of Labile Ferrous Iron
We used RhoNox-1 to detect intracellular labile ferrous iron. RhoNox-1 was kindly provided from Dr Tasuku Hirayama and Professor Hideko Nagasawa. 24 In brief, an unfixed frozen section of the kidney was washed with Hank's Balanced Salt Solution (HBSS) three times and incubated with RhoNox-1 in HBSS (5 μM) in a dark, humidified container at room temperature for 30 min. After washing with HBSS three times, the section was covered with a small drop of the mounting medium, and observed using fluorescence microscopy. In some experiments, the frozen sections were fixed in 10% neutral formaldehyde for 1 min, washed with HBSS, and incubated with RhoNox-1. 25 Then, the sections were incubated with the primary antibody at 4°C overnight in a dark humidified container. Lectin and E-cadherin were used as a marker of the proximal and distal tubules, respectively. In HepG2 cells, the cells were seeded in a 24-well culture plate or a black 96-well microplate. HepG2 was stimulated with SFO for 1 h and then loaded with 5 μM RhoNox-1 in HBSS at 37°C for 30 min. After washing, ferrous iron was observed using fluorescence microscopy or quantitatively measured at 530 and 575 nm for RhoNox-1 using a fluorescence microplate reader (Varioskan Flash, Thermo Fisher Scientific, Waltham, MA, USA).
In Situ Oxidative Stress Detection in Kidney Tissue
Detection of superoxide production in the kidney was evaluated by dihydroethidium (DHE) staining method as described previously. 22 Briefly, non-fixed frozen tissue sections were incubated with DHE in PBS (10 μM) in a dark, humidified container at room temperature for 30 min and then observed using fluorescence microscopy.
Intracellular Reactive Oxidative Species Detection
Intracellular reactive oxidative species (ROS) were detected using 2′,7′-dichlorofluorescin diacetate (DCFH-DA; SigmaAldrich, St Louis, MO, USA). HepG2 was stimulated with SFO for 1 h and then loaded with 10 μM DCFH-DA at 37°C for 30 min. After washing, ROS production was observed using fluorescence microscopy or quantitatively measured at 488 and 532 nm for DCFH-DA using a microplate reader (FilterMax F3 Multi-Mode Microplate Readers, Molecular Devices, Sunnyvale, CA, USA).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed to determine the interaction between the HIF-2α protein and Epo gene promoter containing the hypoxia response element (HRE). Briefly, the HepG2 cells treated with vehicle or SFO, and with or without tempol were crosslinked with formaldehyde at a final concentration of 1.0% for 10 min, then added to 2.5 mM glycine to stop the crosslinking reaction. Then, 
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Inhibitory action of iron on erythropoietin K Oshima et al cells were collected, incubated with cell lysis buffer, and the nuclear fraction was extracted. After sonication and centrifugation, the supernatant fraction was co-immunoprecipitated with HIF-2α protein using agarose beads (Protein A/G plus-Agarose, Santa Cruz Biotechnology). The beads were washed and incubated at 65°C in elution buffer to reverse the cross-links. DNA was purified from the elution buffer and used for PCR. The primer sequence for the HRE-containing region of the human EPO promoter was used as shown previously. 26 The primer sequences, used to amplify the HRE-containing region of the human EPO promoter were as follows: EPO forward primer 5′-TCGTTTTCTGGGAAC CTCCA-3′, and EPO reverse primer 5′-GGAGCCACC TTATTGACCAG-3′.
Hypoxia-Responsive Element Luciferase Reporter Assay
The hypoxia-responsive reporter vector was constructed using three tandem copies of the HRE from the human EPO gene subcloned into the secreted luciferase from the marine copepod Metridia longa transcription unit Inhibitory action of iron on erythropoietin K Oshima et al (pCre-MetLuc2-Reporter plasmid vector, Takara Bio, Shiga, Japan). One hundred nanograms pCre-MetLuc-HRE plasmid vector and 10 ng pSEAP2-Control plasmid vector (Takara Bio) were co-transfected in 1 × 10 4 HepG2 cells using Lipofectamine 2000 (Thermo Fisher Scientific) in a 96-well culture plate. The transfected cells were exposed to the vehicle or SFO for 24 h and then the cell culture medium was harvested and both luciferase and alkaline phosphatase (ALP) activities were measured using Secreted Luciferase Reporter Assay (Takara Bio) and SEAP Reporter Gene Assay (SigmaAldrich Japan K.K., Tokyo, Japan), respectively, according to the manufacturer's instructions. To normalize the transfection efficiency, the RLU of the luciferase chemiluminescence unit was divided by that of the ALP chemiluminescence unit.
Measurement of Plasma EPO Concentration
Plasma EPO concentration was determined by using an ELISA kit, according to the manufacturer's instructions (Mouse Erythropoietin Quantikine ELISA Kit, R&D systems, Minneapolis, MN, USA).
Statistical Analysis
The data are presented as mean ± s.d. An unpaired, two-tailed Student's t-test was used for comparison between the two groups. For comparisons between more than two groups, the statistical significance of each difference was evaluated by post hoc test using Dunnett's method or Tukey-Kramer's method. Statistical significance was indicated by Po0.05.
RESULTS
EPO Expression and Iron Content in
The Kidney with UUO surgery EPO mRNA levels are drastically reduced in kidneys with UUO surgery. 17 Similarly, EPO mRNA expression was decreased in the kidney at 7 days after UUO surgery compared with sham operation (Figure 1a) . We have already demonstrated that renal iron content was significantly augmented in UUO-induced fibrotic kidney in the previous study. 15 
EPO Expression and Iron Content in the Kidney of IronTreated Mice
To examine direct action of iron on EPO expression, we used mice with SFO treatment. Renal iron content was significantly increased in mice with SFO treatment for consecutive five days compared with vehicle-treated mice (vehicle; 12.0 ± 3.6 μg Fe per gram of wet tissue, SFO; 20.8 ± 4.2 μg Fe per gram of wet tissue, n = 3, Po0.05). EPO mRNA expression was decreased in the kidney of SFO-treated mice compared with vehicle-treated mice (Figure 1d) . Similarly, the plasma EPO concentration was also suppressed in SFOtreated mice (Table 4 ). There were no significant differences in hematological parameters of red blood cells between vehicle-and SFO-treated mice (Table 2) . 27 and liver. 26 HIF-2α expression was diminished in the kidneys with UUO and iron treatment compared with the kidneys with sham or vehicle treatment (Figure 1c and f) . These findings suggest that iron accumulation suppresses renal EPO expression through the inhibition of HIF-2α. In contrast, HIF-1α mRNA was not changed and HIF-1α protein was decreased in the kidney of UUO mice (Figure 1b and c) , whereas HIF-1α mRNA was elevated and HIF-1α protein tended to decrease in the kidney of SFO-treated mice ( Figure  1e and f).
HIF-2α
Expression in the Kidney with UUO and Iron-Treated Mice HIF-2α is an important regulator of EPO expression in the kidney
SFO Action on Transition of Fibroblast to Myofibroblast in Kidneys
EPO production occurs in fibroblasts, and loss of EPO production occurs during the transition of fibroblast to myofibroblast in the course of renal fibrosis progression. 16, 17 The fibroblast to myofibroblast transition has an important role in the process of renal fibrosis. 28 Therefore, we checked whether iron was involved in the fibroblast to myofibroblast transition-dependent loss of EPO production. No apparent parenchymal damages were seen in the kidney of SFO-treated mice compared with vehicle-treated mice (Figure 2a) . SFO treatment augmented the expression of PDGF-Rβ and α-SMA proteins in the kidney, compared with vehicle treatment (Figure 2b and c) . Immunohistochemical analysis showed that PDGF-Rβ expression was increased in the renal interstitium of SFO-treated kidneys. The α-SMA expression also increased in the renal interstitium of SFO-treated kidneys. In contrast, it was almost completely localized in vessels in vehicle-treated kidneys. Moreover, PDGF-Rβ and α-SMA expression were colocalized in the renal interstitium of SFO-treated kidneys (Figure 2d ). These results suggest that iron-induced EPO reduction occurs due to an induction of renal fibrotic change and the myofibroblast transition.
The Effect of SFO on EPO mRNA Expression in HepG2 Cells First, we performed the MTS cell proliferation assay to determine the effect of SFO on the viability of HepG2 cells. SFO had no effect of cellular viability at 50, 100, and 200 μg/ml but significantly reduced cell viability at 1000 μg/ml. This result indicates that high concentrations of SFO are toxic for HepG2 Inhibitory action of iron on erythropoietin K Oshima et al cells (Figure 3a) . Therefore, we used SFO at concentrations of 200 μg/ml and below in further studies. To examine the effect of SFO on EPO regulation, we examined EPO mRNA expression after treatment with various concentration of SFO. As shown in Figure 3b , SFO significantly reduced EPO mRNA expression in a dose-dependent manner. HIF-2α mRNA and protein levels were also reduced by SFO treatment in HepG2 cells (Figure 3c and d) . Similarly, the expression of HIF-1α at the mRNA and protein levels decreased in HepG2 cells (Figure 3c and d) . The results of these in vitro experiments are consistent with in vivo results demonstrating the effect of SFO on EPO and HIF-2α expression in the kidney.
The Suppressive Effects of SFO on CoCl 2 or DMOG-induced EPO and HIF-2α Upregulation
We examined the effects of SFO on EPO and HIF-2α expression under hypoxic conditions, using cobalt chloride to mimic conditions of hypoxia induction. EPO mRNA and HIF-2α protein expression were increased by cobalt chloride treatment. The hypoxia-induced increases in EPO mRNA and HIF-2α protein expression were suppressed by combining SFO and cobalt chloride treatments (Figure 3e and f) . DMOG is a prolyl hydroxylase inhibitor drug, and is also used for the induction of HIF expression. As observed with cobalt chloride, DMOG treatment increased EPO mRNA and HIF-2α protein expression, and these increases were inhibited by concomitant SFO treatment (Figure 3g and h). Cobalt chloride-or DMOG-induced HIF-1α protein expression was also decreased by concomitant SFO treatment (Figure 3f and h).
SFO Treatment Induced Oxidative Stress
Excess iron causes oxidative stress by producing hydroxyl radicals via the Fenton reaction. 29 SFO treatment actually Inhibitory action of iron on erythropoietin K Oshima et al increased labile ferrous iron mainly in both the proximal and distal tubule of the kidney (Figure 2e and g ), and HepG2 cells (Figure 4a ), suggesting to iron-induced oxidative stress consequent to Fenton reaction. Here, we showed that SFO induced oxidative stress in the kidney (Figure 2f ). SFO-induced oxidative stress seemed to be dominantly localized in the glomeruli and a part of the proximal tubule (Figure 2h ). SFO-induced oxidative stress was also observed in HepG2 cells (Figure 4b) , and it was diminished by the antioxidant compound, tempol (Figure 4c (Figure 4d-f) . SFO-induced reduction in HIF-1α protein was restored by tempol treatment (Figure 4f ). These findings indicate that SFO-mediated suppression of EPO and HIF-2α expression occurs via SFO-induced oxidative stress.
SFO Suppressed the Interaction Between the HIF-2α Protein and Epo-HRE Containing Promoter
We performed ChIP to examine the interaction between the HIF-2α protein and Epo-HRE containing promoter region. As shown in Figure 4g , SFO treatment reduced HIF-2α binding to the Epo promoter. The suppressive action of SFO Inhibitory action of iron on erythropoietin K Oshima et al on the HIF-2α and Epo gene promoter interaction was restored by tempol treatment. These results suggest that SFO-induced EPO downregulation was due to the inactivation of HIF-2α binding to the Epo-HRE containing promoter region.
The Promoter Activity of HRE was Inhibited by SFO Treatment in HepG2 Cells
We also examined the effect of SFO on HRE promoter activity by luciferase assay. As shown in Figure 4h , SFO diminished the promoter activity of HRE by 50%, indicating the inhibitory action of SFO on Epo through transcriptional inactivity of HIF.
Effect of SFO on HIF-regulated genes HIF is a well-known transcriptional regulator for many genes.
In addition to Epo, we assessed several HIF-regulated genes, such as Vegf, Phd3, and Pgk1. In the in vivo studies, SFO treatment elevated mRNA expression of these three genes (Figure 5a ). However, only Phd3 mRNA expression was augmented by SFO treatment in HepG2 cells (Figure 5b ). PHD3 has a crucial role in the regulation of HIF-2, 30 indicating the involvement of iron in HIF-2α regulation.
Inhibitory Effect of SFO on Anemia-Induced EPO upregulation Finally, we examined whether SFO treatment suppresses anemia-induced EPO upregulation by using mice with Inhibitory action of iron on erythropoietin K Oshima et al phlebotomy-induced anemia. Phlebotomy-induced anemia in mice, and no differences in hematological parameters were observed in these mice regardless of SFO treatment ( Table 3) . As shown in Figure 5c and Table 4 , anemia induced an increase in renal Epo mRNA expression as well as plasma EPO concentration, were suppressed by SFO treatment. Moreover, anemia-induced HIF-2α expression was also inhibited in SFO-treated mice with phlebotomy ( Figure 5d ).
DISCUSSION
In CKD, patients with renal anemia are commonly administered parenteral iron supplementation. However, iron treatment itself has adverse effects on various tissues through iron-related oxidative stress production. In the present study, we found that parenteral iron treatment reduced EPO mRNA and HIF-2α protein expression in the mouse kidney. Notably, iron treatment augmented oxidative stress production in both in vivo and in vitro experiments, and tempol could restore iron-induced reduction of EPO and HIF-2α expression in HepG2 cells. Moreover, iron suppressed HIF-2α binding to the Epo-HRE containing promoter, which was ameliorated by tempol. These results suggest that iron reduces EPO expression through HIF-2α inactivation via oxidative stress production. Renal fibrosis is an important factor in the progression of CKD leading to end-stage renal disease, 31 and renal anemia, a Data are means ± s.d; n = 3; **Po0.01 vs control mice.
Inhibitory action of iron on erythropoietin K Oshima et al complication of CKD, develops along with renal fibrosis. The primary cause of renal anemia is inadequate EPO production consequent to loss of renal-EPO-producing cells due to renal fibrosis. 16 The murine UUO model is widely recognized to induce renal fibrosis with reduced EPO expression. Renal EPO expression is drastically reduced at day 1 or later after UUO surgery. 17 In the same murine UUO model, excess iron accumulation is observed in UUO-induced fibrotic kidneys compared with those of sham-operated mice. 15 In addition, we confirmed reduced EPO expression in UUO fibrotic kidneys. Consistent with the association between renal fibrosis and iron accumulation, several studies have shown that iron content is increased in fibrotic kidneys of the angiotensin II-infused rat, 32 Dahl salt-sensitive rat, 33 and 5/6 nephrectomized rat. 34 We, and others, have shown the antifibrotic effect of tissue iron reduction using iron chelators or iron restriction chow on the kidney. 15, 33, 34 Here, direct SFO treatment diminished renal EPO expression in the kidney with increased iron content. Therefore, there is a close relationship between iron accumulation and renal fibrosis, resulting in the reduction of EPO expression. The EPO gene promoter contains a HRE region. HIF promotes EPO transcription through binding to HRE in the Epo promoter. 26, 35 It has been shown that HIF-1 and HIF-2 transcriptionally regulate EPO expression. However, using renal-specific HIF-2α knockout mice, it has been demonstrated that renal EPO expression is predominantly regulated by HIF-2α and not by HIF-1α. 36 Using an siRNA approach in Hep3B cells, constituting a hepatoma cell line, 37 and mice with conditional hepatic HIF-2α deletion, it has been shown that EPO gene induction is largely dependent on HIF-2, not HIF-1 in the liver. 26 Thus, HIF-2α is recognized as a key regulator of EPO expression in both the kidney and liver.
In this study, SFO treatment reduced HIF-2α expression, and HIF-2α protein binding to the Epo promoter region. In addition, SFO-induced HIF-2α inactivation was ameliorated by the antioxidant compound, tempol, indicating the involvement of iron-mediated oxidative stress in HIF-2α regulation. HIFs are generally regulated by posttranscriptional mechanisms that determine the rate of HIF protein degradation, 38 and its binding ability. 39 Iron itself is shown to antagonize HIF-mediated induction of EPO gene expression induced by cobalt chloride, 40 and iron supplementation reduces HIF-1α expression levels even under normoxia in PC3 cells. 41 This is the first study to describe the association between iron and HIF-2α, and to suggest that the preventive action of iron on EPO expression is mediated through a HIF-2α-dependent signaling pathway. Prolyl hydroxylase domain (PHD) also has a crucial role in regulating HIF protein stability, and PHD activity is stimulated by ferric iron, and suppressed by iron chelation. 42 Correspondingly, DMOG, a PHD inhibitor, induced EPO expression, which was also attenuated by concomitant SFO treatment in HepG2 cells. In addition, PHD3 is known to be a regulator of HIF-2, 30 and SFO increased Phd3 mRNA expression in both the kidney and HepG2 cells, indicating the involvement of iron-induced PHD3 upregulation in HIF-2α reduction. Therefore, SFO-mediated EPO reduction might be involved in the destabilization of HIF-2α protein via the restoration of DMOG-inhibited PHD activity. In contrast to phd3 mRNA expression, mice with SFO treatment showed increased mRNA expression of Vegf and PGK1 and these genes were not changed in HepG2 cells with SFO treatment. The different expression of HIF-regulated genes induced by iron might be due to tissue or cell from different organ.
Oxidative stress is proposed to participate in regulating the protein stability and transcriptional activity of HIF. H 2 O 2 destabilizes HIFs protein under hypoxia. 43, 44 Oxidative stresses such as diamide, N-ethylmaleimide, and H 2 O 2 also inhibit the DNA binding activity of HIF-1. 39 H 2 O 2 suppresses hypoxia-induced EPO production in HepG2 cells, 45 which might be due to oxidative stress-mediated HIF inactivation. Taken together, iron-induced oxidative stress could be responsible for protein stabilization and DNA binding activity of HIF. Moreover, tempol ameliorated SFO-induced inhibition of the HIF-2α-EPO signaling pathway without affecting intracellular iron content. Therefore, concomitant treatment of antioxidant drugs might be effective for reducing the oxidative stress induced by iron supplementation.
HIF proteins are involved in the post-transcriptional regulation of protein expression and activity as well as the regulation of mRNA transcription. Page et al. 46 have shown that HIF-1α expression is increased by angiotensin II via diacylglycerol-sensitive protein kinase C-dependent transcriptional regulation in addition to the ROS-phosphatidylinositol 3-kinase pathway-dependent translational pathway. A recent study has shown that mice deficient in iron-regulatory protein 1 exhibit HIF-2α protein accumulation due to de-repression of HIF-2α mRNA and induce renal EPO expression. 47 However, inconsistent with the above results, we have shown that SFO treatment decreased HIF-2α mRNA expression in mice kidney and HepG2 cells, indicating that iron negatively regulates HIF-2α expression at the transcriptional level in this study. Moreover, SFO-induced HIF-2α mRNA downregulation was not changed by tempol treatment, even though SFO-mediated HIF-2α protein downregulation was reversed. This suggests that iron transcriptionally regulates HIF-2α expression independent of iron-mediated oxidative stress, in Inhibitory action of iron on erythropoietin K Oshima et al addition to the post-transcriptional regulation of protein degradation and the DNA binding activities of HIF-2α. Further studies are necessary to clarify the mechanism of iron regulation on HIF-2α activation. Recent studies demonstrate that renal EPO production cells are derived from fibroblasts, and the transition of fibroblast to myofibroblast is the main cause of renal fibrosis 28 and loss of EPO production in CKD. 16, 17 We previously reported that the UUO-induced increase of α-SMA expression in the interstitium was reduced by iron chelation. 15 This indicates that iron participates in the myofibroblast transition during the process of renal fibrosis. Here, we also found that PDGF-Rβ (a fibroblast marker) and α-SMA (a myofibroblast marker) expression were enhanced, and that PDGF-Rβ and α-SMA were colocalized in the tubulo-interstitium in kidneys with SFO treatment. These findings suggest that iron promotes renal fibrotic change with transition of fibroblasts to myofibroblasts, in part leading to an iron-induced reduction of EPO expression. In contrast, superoxide, as well as ferrous iron, was not observed in the renal tubulo-interstitium. Therefore, further studies are required to clarify the interaction between fibroblast, oxidative stress, and iron in the kidney.
In the present study, SFO-treated mice showed the reduced plasma EPO concentration and the lower level of RBC, Hb, and Ht compared with vehicle-treated mice, suggesting the decrease of erythropoiesis due to iron-induced reduction of EPO production. On the other hand, WBC counts were elevated by SFO treatment. Intravenous iron treatment induces protein oxidation, which positively correlates to CRP levels in hemodialysis patients, 48 indicating the association between iron-induced oxidative stress and inflammation. Therefore, iron treatment perhaps causes inflammation as well as oxidative stress, resulting in the increased number of WBC.
In regard to mice model of UUO, HIF-1α mRNA was not changed and HIF-1α protein was diminished in UUO kidney at day 7 after surgery in our study. Souma et al. 17 demonstrate that HIF-1α mRNA was increased in UUO kidney at day 2 after surgery. This discrepancy of HIF-1α expression might be responsible for the different sampling point after UUO induction or the discordance of protein and mRNA expression.
In conclusion, parenteral iron supplementation reduced EPO gene expression via oxidative stress-induced HIF-2α inactivation. These findings suggest a new potential risk of parenteral iron supplementation and a causative role of therapeutic excess iron in the further deterioration of endogenous erythropoietin production in CKD.
